Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00306748 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation
A Phase 2 study, sponsored by Ironwood Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00306748 is a Phase 2 study that has completed, run by Ironwood Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT00306748, a Phase 2 study, has completed, sponsored by Ironwood Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and gastrointestinal pharmacodynamics (stool frequency, stool consistency, stool ease of passage, stool completeness of evacuation) of MD-1100 acetate administered daily for 14 days.
Interventions
- DRUG MD-1100 Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-03 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00306748
The ClinicalTrials.gov registry entry for NCT00306748 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ironwood Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MD-1100 Acetate is the first listed.
NCT00306748 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00306748 about?
NCT00306748 is a clinical study titled "Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation". The purpose of this study is to determine the safety and gastrointestinal pharmacodynamics (stool frequency, stool consistency, stool ease of passage, stool completeness of evacuation) of MD-1100 acetate administered daily for 14 days.
What is the current status of trial NCT00306748?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2006-03. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00306748?
The interventions under investigation include: MD-1100 Acetate (DRUG).
Who is sponsoring clinical trial NCT00306748?
This trial is sponsored by Ironwood Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.